BRPI0822415A2 - Conjugado de hidróxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição para matar tumor, e, métodos para produzir o conjugado de hidroxipolímero modificado e para tratar câncer. - Google Patents

Conjugado de hidróxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição para matar tumor, e, métodos para produzir o conjugado de hidroxipolímero modificado e para tratar câncer.

Info

Publication number
BRPI0822415A2
BRPI0822415A2 BRPI0822415-3A BRPI0822415A BRPI0822415A2 BR PI0822415 A2 BRPI0822415 A2 BR PI0822415A2 BR PI0822415 A BRPI0822415 A BR PI0822415A BR PI0822415 A2 BRPI0822415 A2 BR PI0822415A2
Authority
BR
Brazil
Prior art keywords
modified hydroxypolymer
hydroxypolymer conjugate
conjugate
modified
producing
Prior art date
Application number
BRPI0822415-3A
Other languages
English (en)
Inventor
Anders Holmberg
Original Assignee
Dextech Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dextech Medical Ab filed Critical Dextech Medical Ab
Publication of BRPI0822415A2 publication Critical patent/BRPI0822415A2/pt
Publication of BRPI0822415B1 publication Critical patent/BRPI0822415B1/pt
Publication of BRPI0822415B8 publication Critical patent/BRPI0822415B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0822415A 2008-04-07 2008-04-07 conjugado de hidroxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição tendo efeito de matar célula de tumor, e, método para produzir o conjugado de hidroxipolímero modificado BRPI0822415B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/054139 WO2009124580A1 (en) 2008-04-07 2008-04-07 Modified hydroxypolymer conjugates with bone seeking and tumor killing moieties

Publications (3)

Publication Number Publication Date
BRPI0822415A2 true BRPI0822415A2 (pt) 2015-06-16
BRPI0822415B1 BRPI0822415B1 (pt) 2020-09-24
BRPI0822415B8 BRPI0822415B8 (pt) 2021-05-25

Family

ID=39940614

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822415A BRPI0822415B8 (pt) 2008-04-07 2008-04-07 conjugado de hidroxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição tendo efeito de matar célula de tumor, e, método para produzir o conjugado de hidroxipolímero modificado

Country Status (9)

Country Link
US (1) US20110118207A1 (pt)
EP (1) EP2274018B1 (pt)
JP (1) JP5242769B2 (pt)
CN (1) CN101990442B (pt)
BR (1) BRPI0822415B8 (pt)
CA (1) CA2719295C (pt)
IL (1) IL208424A (pt)
MX (1) MX2010011071A (pt)
WO (1) WO2009124580A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI127538B (en) * 2016-06-22 2018-08-31 Dextech Medical Ab MODIFIED Dextran Conjugates
EP4538300B1 (en) 2023-10-13 2025-11-26 Dextech Medical AB One pot gmp scalable production method for the synthesis of dextran-guanidine-bisphosphonate conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011913A (en) * 1985-06-28 1991-04-30 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
DE19621038A1 (de) * 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
US6288124B1 (en) * 1998-05-22 2001-09-11 Rima Kaddurah-Daouk Methods of inhibiting undesirable cell growth using an aminoguanidine compound
SE9803482D0 (sv) * 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
US6800668B1 (en) * 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
KR100648515B1 (ko) * 2004-05-04 2006-11-27 (주)아모레퍼시픽 비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제
FI119513B (fi) * 2007-03-07 2008-12-15 Dextech Medical Ab Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin

Also Published As

Publication number Publication date
MX2010011071A (es) 2010-11-12
US20110118207A1 (en) 2011-05-19
JP2011516508A (ja) 2011-05-26
CN101990442A (zh) 2011-03-23
CA2719295C (en) 2015-10-06
IL208424A0 (en) 2010-12-30
EP2274018B1 (en) 2013-12-18
EP2274018A1 (en) 2011-01-19
JP5242769B2 (ja) 2013-07-24
WO2009124580A1 (en) 2009-10-15
BRPI0822415B1 (pt) 2020-09-24
CA2719295A1 (en) 2009-10-15
CN101990442B (zh) 2013-03-27
IL208424A (en) 2015-03-31
BRPI0822415B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
BRPI0814542A2 (pt) Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
LT3124043T (lt) Nauja imunoterapija prieš tam tikrus navikus, įskaitant neuronų ir galvos smegenų navikus
EA201171367A1 (ru) Винилиндазолильные соединения
WO2009129246A3 (en) Compositions and methods for preparing and using same
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
CL2008001069A1 (es) Compuestos derivados de tetrahidroindazoles y tetrahidroindoles; procedimiento de preparacion; y su uso para tratar una enfermedad o trastorno relacionado con la proliferacion celular.
BRPI0911350A2 (pt) conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 51/06 (2006.01), A61K 47/54 (2017.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed